Multidrug Resistant Tuberculosis Completed Phase 2 / 3 Trials for Pretomanid (DB05154)

Back to Multidrug Resistant Tuberculosis

Also known as: MDR-TB / MDR Tuberculosis / Multidrug-Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, MDR / MDR TB / Multi Drug Resistant Tuberculosis / Tuberculosis, Multidrug-Resistant / Multi-Drug Resistant Tuberculosis / TB Multi-drug Resistant / Multidrug resistant tuberculosis (disorder) / Tuberculosis / Tuberculosis (disorder) / Tuberculosis NOS / Tuberculosis NOS (disorder) / Infection TBC / Infection tuberculosis / Infection caused by Mycobacterium tuberculosis (disorder) / TB / Tuberculous (disorder) / Tuberculous (qualifier value) / Tuberculous infections

Indication	Status	Phase
DBCOND0041129 (Multidrug Resistant Tuberculosis)	Completed	2 / 3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03338621	Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients	Treatment	Bedaquiline (DB08903) Ethambutol (DB00330) Isoniazid (DB00951) Moxifloxacin (DB00218) Pretomanid (DB05154) Pyrazinamide (DB00339) Rifampicin (DB01045)